Definitive Healthcare (NASDAQ:DH) Updates FY 2024 Earnings Guidance

Definitive Healthcare (NASDAQ:DH) issued an update on its FY 2024 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of 0.360-0.380 for the period, compared to the consensus estimate of 0.380. The company issued revenue guidance of $255.0 million-$261.0 million, compared to the consensus revenue estimate of $266.3 million. Definitive Healthcare also updated its Q2 2024 guidance to 0.080-0.090 EPS.

Definitive Healthcare Stock Down 3.4 %

Shares of NASDAQ DH traded down $0.18 during trading on Thursday, hitting $5.17. The stock had a trading volume of 3,323,524 shares, compared to its average volume of 643,916. Definitive Healthcare has a 12 month low of $4.38 and a 12 month high of $12.45. The company has a debt-to-equity ratio of 0.20, a current ratio of 2.31 and a quick ratio of 2.31. The company has a market capitalization of $608.97 million, a PE ratio of -2.90, a PEG ratio of 6.12 and a beta of 1.41. The firm has a fifty day moving average of $7.61 and a two-hundred day moving average of $8.27.

Definitive Healthcare (NASDAQ:DH) last posted its earnings results on Wednesday, February 28th. The company reported ($0.01) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.01 by ($0.02). Definitive Healthcare had a positive return on equity of 0.43% and a negative net margin of 80.40%. The firm had revenue of $65.93 million during the quarter, compared to the consensus estimate of $66.01 million. As a group, equities research analysts forecast that Definitive Healthcare will post 0.11 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on DH shares. Morgan Stanley lowered shares of Definitive Healthcare from an overweight rating to an equal weight rating and reduced their price target for the company from $11.50 to $9.00 in a research report on Wednesday. Canaccord Genuity Group reduced their price target on shares of Definitive Healthcare from $10.00 to $8.00 and set a hold rating for the company in a research report on Wednesday. Needham & Company LLC restated a hold rating on shares of Definitive Healthcare in a research report on Wednesday. Deutsche Bank Aktiengesellschaft reduced their price target on shares of Definitive Healthcare from $10.00 to $7.00 and set a hold rating for the company in a research report on Thursday. Finally, Barclays reduced their price target on shares of Definitive Healthcare from $11.00 to $7.00 and set an equal weight rating for the company in a research report on Thursday. Nine research analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of Hold and an average price target of $9.94.

About Definitive Healthcare

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.